What is the Purpose of this Study?
Primary Objective: To compare infinatamab deruxtecan (I-DXd) to docetaxel with respect to overall survival (OS) in participants with mCRPC. To compare I-DXd to docetaxel with respect to radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) in participants with mCRPC. Secondary Objectives: To evaluate the TFST of participants treated with I-DXd compared with participants treated with docetaxel. To evaluate the OR and DOR per PCWG Modified RECIST 1.1 as assessed by BICR of participants treated with I-DXd compared with participants treated with docetaxel. To evaluate the Time to Pain Progression (TTPP) of participants treated with I-DXd compared with participants treated with docetaxel. To evaluate the time to PSA progression of participants treated with I-DXd compared with participants treated with docetaxel. To evaluate the
Eligibility
- * Has diagnosis of metastatic castration-resistant prostate cancer (mCRPC)
- * Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months prior to entering the study
Where can I participate?
- CS Cancer at Beverly Hills : Maria Tarallo
- CS Cancer at Cedars-Sinai Medical Center : Maria Tarallo
More about this Clinical Trial
What is the full name of this clinical trial?
MK-2400-001: A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer